[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fxY8DEsFl_WXe6VaufXc2PTyutBYv0Iq90jVc8n6a9Qk":8,"$fyBkxAQSmxuJYarnO1ECkB8ADKwI6Tgsqh5ZPiEr8-iM":55,"$fPYtvMqVaXrZTgEs88fCg1k00FNkogsRyjJTBXf5W9yQ":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},74900,870955,[],"https://cdn.yishi-tong.com/console/store-unknown/uF7OMd0P_hB1LaAPsAH23kXFsYY6stA4.png","荆涛","桓台县人民医院","肝胆外科","副主任医师",3,0,"胆管癌晚期用药详解：吉西他滨、顺铂与帕博利珠单抗的正确使用指南","","https://ystcdn.venuertc.com/venue/AI/c21f4ba6-a7f2-4615-b3c6-fe7b73226188.jpg","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  胆管癌晚期用药详解：吉西他滨、顺铂与帕博利珠单抗的正确使用指南\n\u003C/div>\n\u003Cdiv class=\"drug-guide-intro\">\n 说起吉西他滨、顺铂和帕博利珠单抗，许多人会想到它们在综合抗肿瘤方案中的应用。这三种药物各自属于化疗与免疫调节领域，常被用于晚期患者的治疗。本文将细致介绍它们的成分、用法、注意事项、常见副作用以及安全用药的技巧，共7个关键方面，帮您理清用药细节，规避风险。\n\u003C/div>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #e2eafc 60%, #fff 100%);\">\n    01 主要成分与剂型\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\u003Cb>吉西他滨（Gemcitabine）\u003C/b>：属抗代谢类紫杉化合物，常见剂型为注射用粉剂，规格多为200mg、1000mg等。\u003C/li>\n      \u003Cli>\u003Cb>顺铂（Cisplatin）\u003C/b>：属于铂类化疗药，剂型为注射液，常见规格为10mg、50mg等。\u003C/li>\n      \u003Cli>\u003Cb>帕博利珠单抗（Pembrolizumab）\u003C/b>：免疫检查点抑制剂，产品多为注射液或冻干粉剂，常用规格为100mg/瓶。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">💡使用时需由专业医护人员配置与给药。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #fef6e4 60%, #fff 100%);\">\n    02 作用机制简析\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">吉西他滨：\u003C/span>\n        通过干扰DNA的合成，阻止肿瘤细胞快速分裂与复制，从而起到抑制作用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">顺铂：\u003C/span>\n        使DNA发生交联损伤，阻断细胞分裂过程，令肿瘤细胞衰亡。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">帕博利珠单抗：\u003C/span>\n        作为PD-1免疫检查点抑制剂，解除肿瘤对免疫系统的“刹车”，激活自身免疫力清除异常细胞。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">🧬三者靶点不同，联合使用可协同提升治疗效能。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #ebe4fd 60%, #fff 100%);\">\n    03 用药方法与给药流程\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">吉西他滨：\u003C/span>\n        需静脉滴注，常于多日化疗方案中首日或首两日单独给药。具体剂量与间隔由医生依据体表面积与耐受情况决定。每个疗程后需间隔，常见一个周期为3-4周。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">顺铂：\u003C/span>\n        一般于吉西他滨用后或同期，同样通过静脉给药。需确保患者水化充足以防肾毒性，给药片段可搭配保护剂使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">帕博利珠单抗：\u003C/span>\n        通常每三周静脉滴注一次。剂量基于体重或按照固定剂量，给药时间30分钟左右。治疗周期的持续时间和疗程需根据疗效与耐受反复评估。\n      \u003C/li>\n      \u003Cli class=\"drug-point-highlight\">正确做法：仅能在临床专科或具备资质的医疗机构完成上述用药，严禁自行操作！\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">⏰忘记疗程时间，务必及时与就医单位联系。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #eaffea 60%, #fff 100%);\">\n    04 药物相互作用必须关注\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        吉西他滨与顺铂联合用药时，顺序与间隔时间会影响药效和副作用，具体应用需严格遵照主治医师制定的方案。\n      \u003C/li>\n      \u003Cli>\n        帕博利珠单抗与既往免疫抑制药物同用时，可能影响免疫疗效或增加免疫副反应。\n      \u003C/li>\n      \u003Cli>\n        顺铂与多种肾毒性药物（如某些抗生素）同用可增加肾损伤风险，需提前告知医生目前所用药物。\n      \u003C/li>\n      \u003Cli>\n        若需应用其他补充治疗（如止吐、护肝药），必须征得医师认可，避免药物叠加反应。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b>每一次化疗前如实汇报所有在用的药、健康补剂及过敏史，便于医护团队做出合理调整。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">⚠️随意加用其他药物前，务必咨询主治医师。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #f3ecdf 60%, #fff 100%);\">\n    05 特殊人群用药注意事项\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">老年患者：\u003C/span>药物代谢慢，副作用风险增加，剂量与间隔时长需个体化。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">肾、肝功能减退者：\u003C/span>顺铂需评估肾功能，肝功能异常时使用吉西他滨与帕博利珠单抗要格外谨慎。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">孕妇和哺乳期女性：\u003C/span>三者均不推荐用于怀孕或哺乳期，涉及生育计划者需提前与医生沟通可能风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">儿童与青少年：\u003C/span>不属于常规适用人群，用药方案须依托严格的医疗项目与伦理审批。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>需遵守：\u003C/b>严格遵守医生根据年龄、体重和器官功能调整的个体化方案，切勿照搬他人经验。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">👩‍⚕️医生评估后才能调整剂量和频率。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #ffe0eb 60%, #fff 100%);\">\n    06 常见不良反应与处理方法\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">吉西他滨：\u003C/span>常出现骨髓抑制（如白细胞减少），可能伴随疲乏、脱发。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">顺铂：\u003C/span>带来肾功能损害和恶心呕吐，也可引起耳鸣、神经感觉异常。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">帕博利珠单抗：\u003C/span>可有免疫相关副反应，如皮肤、内分泌系统异常或肺炎、肠炎等罕见情况，需耐心监测。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-highlight\">处理方法：\u003C/span>出现持续发热、出血、严重疲劳、感染迹象或呼吸困难时，应立即回医院就诊，切不可擅自减药或停药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-highlight\">临床病例：\u003C/span>一位接受吉西他滨和顺铂联合用药的患者，因骨髓抑制表现，中途暂停后经调整方案恢复顺利，再次输注时严格按间隔周期执行。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">🚨出现异常反应时要早发现、早处理。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #e8f8f5 60%, #fff 100%);\">\n    07 储存方法与用药遗忘处理\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">储存要求：\u003C/span>三种药物均要求避光、密封、低温（2℃-8℃）冷藏保存。配制好的溶液建议在24小时内用毕，剩余部分需按照医疗垃圾处理。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">过期处理：\u003C/span>不得使用过期药品或外观有变色、沉淀现象的药液，残余药品应交由专业机构销毁。\n      \u003C/li>\n      \u003Cli>\n        \u003Cspan class=\"drug-point-subtitle\">漏服处理：\u003C/span>如疗程内出现用药遗漏，请立刻与医师联系，遵从调整后的补药流程，不要自行补打或随意更改疗程。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>小贴士：\u003C/b>家庭常备日用品与这些药物必须严格分开放置，防止误用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">🥶正确储存直接影响药效的稳定性与安全性。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #fafafa 60%, #fff 100%);\">\n    08 真实用药经验分享\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>临床上有患者在联合吉西他滨、顺铂及帕博利珠单抗方案时因提前反馈疲劳、低热，及时调整剂量和疗程，顺利规避了严重副作用。\u003C/li>\n      \u003Cli>一位女性患者在实施免疫治疗阶段，因定期体检发现免疫副反应，立即配合医生紧急处理后，整体疗效与安全性得到保障。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">📋真实用药经验强调主动沟通和监测的重要性。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #e4ffe4 60%, #fff 100%);\">\n    09 关键数据与用药安全总结\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cul class=\"drug-point-list\">\n      \u003Cli>临床数据表明，吉西他滨和顺铂联合方案的药效响应率可达25-30%\u003Csup>[1]\u003C/sup>，副反应发生率整体在50%以上，需重点关注血象变化。\u003C/li>\n      \u003Cli>帕博利珠单抗的不良反应发生率约20%，但多数可逆，联合使用需严密监控免疫相关反应\u003Csup>[2]\u003C/sup>。\u003C/li>\n      \u003Cli>药品说明书提示，这些药物应严格按照专业标准储存与给药，且需密切观察各项指标。\u003C/li>\n      \u003Cli>安全用药的关键在于精准给药、规范监测、主动报告不良事件。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"drug-point-emoji\">🔑牢记每一步操作细节，疗效与安全才有保障。\u003C/div>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section-summary\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #e2eafc 60%, #fff 100%);\">\n    结语与整体提醒\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content\">\n    \u003Cp>\n    吉西他滨、顺铂和帕博利珠单抗作为现代抗肿瘤药物，各有独特机制和使用规范，协同作用需高度重视。合理给药、关注每个周期的小变化、及时报告异常、科学保存药品——这些细节决定疗效与安全。如果亲友需要类似治疗，请务必鼓励定期随访，遇到疑问要向专业医护请教，切勿自行中断或调整方案。正确用药，才是通向健康的第一步。\n    \u003C/p>\n  \u003C/div>\n\u003C/section>\n\n\u003Csection class=\"drug-section-ref\">\n  \u003Cdiv class=\"drug-section-title\" style=\"background: linear-gradient(to right, #fef6e4 60%, #fff 100%);\">\n    参考文献\n  \u003C/div>\n  \u003Cdiv class=\"drug-section-content-ref\">\n    \u003Col>\n      \u003Cli>\n        Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., ... & Bridgewater, J. (2010). \u003Ci>Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer\u003C/i>. New England Journal of Medicine, 362(14), 1273-1281.\n      \u003C/li>\n      \u003Cli>\n        Marabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J. P., ... & Emens, L. A. (2020). \u003Ci>Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study\u003C/i>. Journal of Clinical Oncology, 38(1), 1-10.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/section>\n\n\u003Cstyle>\n.drug-guide-title {\n  font-size: 2.2em;\n  font-weight: bold;\n  color: #364670;\n  padding: 40px 0 18px 0;\n  text-align: center;\n  letter-spacing: 1px;\n  background: #e2eafc;\n  border-radius: 12px 12px 0 0;\n}\n.drug-guide-intro {\n  margin: 20px auto 32px auto;\n  max-width: 1100px;\n  font-size: 1.12em;\n  padding: 24px 28px 18px 28px;\n  background: #f9fbff;\n  font-family: 'PingFang SC', 'Microsoft Yahei', Arial, sans-serif;\n  border-radius: 10px;\n  color: #3a3a3a;\n}\n\n.drug-section {\n  margin: 34px auto;\n  background: #fff;\n  max-width: 1080px;\n  border-radius: 14px;\n  box-shadow: 0 2px 10px 0 #eceffc;\n  overflow: hidden;\n}\n.drug-section-title {\n  font-size: 1.25em;\n  font-weight: 600;\n  color: #454c7c;\n  padding: 22px 30px 13px 30px;\n  letter-spacing: 0.5px;\n  border-top-left-radius: 14px;\n  border-top-right-radius: 14px;\n}\n.drug-section-content, .drug-section-content-ref {\n  padding: 20px 40px 30px 40px;\n  font-size: 1.07em;\n  color: #334355;\n  font-family: 'PingFang SC', 'Microsoft Yahei', Arial, sans-serif;\n  line-height: 1.8;\n}\n.drug-point-list {\n  margin-left: 16px;\n  margin-bottom:8px;\n}\n.drug-point-list li {\n  margin: 12px 0;\n  padding-left: 12px;\n  position: relative;\n  font-size: 1em;\n}\n.drug-point-subtitle {\n  color: #587cc8;\n  font-weight: 500;\n}\n.drug-point-emoji {\n  padding: 13px 0 0 4px;\n  font-size: 1.15em;\n  color: #599187;\n  letter-spacing: 1px;\n  font-weight: 400; \n}\n.drug-point-highlight {\n  color: #d08e33;\n  font-weight: 600;\n}\n\n.drug-section-summary {\n  margin: 38px auto;\n  background: #f9fbff;\n  max-width: 1080px;\n  border-radius: 16px;\n  border-left: 6px solid #8ca7ec;\n  box-shadow: 0 0 7px 1px #eaedf6;\n  overflow: hidden;\n}\n.drug-section-ref {\n  margin: 45px auto 65px auto;\n  background: #fafafa;\n  max-width: 1050px;\n  border-radius: 13px;\n  box-shadow: 0 1px 4px 0 #eaf0fa;\n}\n.drug-section-content-ref {\n  padding: 18px 40px 24px 45px;\n  color: #525457;\n  font-size: 1em;\n  line-height: 1.7;\n}\n@media (max-width: 600px) {\n  .drug-guide-title, .drug-section, .drug-section-summary, .drug-section-ref {\n    max-width: 98%;\n    padding-left: 2%;\n    padding-right:2%;\n  }\n  .drug-section-title, .drug-section-content, .drug-section-content-ref { padding: 18px 3% 22px 3%; }\n}\n\u003C/style>","\u003Cdiv id=\"material_title\" class=\"drug-guide-title\">\n  胆管癌晚期用药详解：吉西他滨、顺铂与帕博利珠单抗的正确使用指南\n\u003C/div>\n\u003Cdiv cla",573,"2025-12-02 01:02:32","胆管癌, 吉西他滨, 顺铂, 帕博利珠单抗, 抗肿瘤, 化疗药物, 免疫治疗, 常见副作用","本文详细介绍了胆管癌晚期的三种主要治疗药物：吉西他滨、顺铂与帕博利珠单抗，包括用法、注意事项及副作用，帮助患者安全用药与有效治疗。","2026-01-03 21:00:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]